Giovanni Caforio (Christopher Goodney/Bloomberg via Getty Images)
October 5, 2020 07:10 AM EDTUpdated 11:07 AM
Deals

Bris­tol My­ers of­fers a big pre­mi­um to reel in MyoKar­dia's car­dio pipeline with a $13B buy­out

John Carroll

Editor & Founder

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Ex­clu­sive: Degra­da­tion start­up rais­es $39M for piv­ot to PRO­TACs and clin­i­cal en­try

Sin­ga­pore car­dio gene ther­a­py biotech col­lects $45M as it plots Eu­rope ex­pan­sion

Bri­an Arm­strong’s NewLim­it rais­es a $130M Se­ries B, lay­ing out road map for an­ti-ag­ing drugs

Bris­tol My­ers to lay off over 500 work­ers in New Jer­sey

Ver­tex touts promis­ing first few months of launch for non-opi­oid pain drug Jour­navx

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times